Microparticles from patients with metabolic syndrome induce vascular hypo-reactivity via Fas/Fas-ligand pathway in mice

PLoS ONE

Volumn 6, Issue 11, 2011, Pages

  Agouni, Abdelali ^a,b,e,f   Ducluzeau, Pierre Henri ^a,c   Benameur, Tarek ^a   Faure, Sébastien ^a   Sladkova, Martina ^a,d   Duluc, Lucie ^a   Leftheriotis, Georges ^a   Pechanova, Olga ^a   Delibegovic, Mirela ^b   Martinez, Maria Carmen ^a   Andriantsitohaina, Ramaroson ^a  

^a INSERM   (France)

^b UNIVERSITY OF ABERDEEN   (United Kingdom)

^c ANGERS UNIVERSITY HOSPITAL   (France)

^d INSTITUTE OF CHEMISTRY   (Slovakia)

^e UNIVERSITÉ D'ANGERS   (France)

^f UNIVERSITY OF SURREY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2; FAS ANTIGEN; FAS LIGAND; INDUCIBLE NITRIC OXIDE SYNTHASE; MONOCYTE CHEMOTACTIC PROTEIN 1; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; N(G) NITROARGININE; PROSTACYCLIN; PROSTAGLANDIN SYNTHASE; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SEROTONIN; CCL2 PROTEIN, MOUSE; FAS PROTEIN, MOUSE; NITRIC OXIDE;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA CONSTRICTION; ARTICLE; BLOOD VESSEL FUNCTION; BLOOD VESSEL REACTIVITY; CELL ACTIVITY; CELL ISOLATION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME RELEASE; ENZYME SYNTHESIS; EX VIVO STUDY; FEMALE; HUMAN; HUMAN CELL; IN VIVO STUDY; MALE; MEMBRANE MICROPARTICLE; METABOLIC SYNDROME X; MOUSE; MYOGRAPHY; NITROSATIVE STRESS; NONHUMAN; OXIDATIVE STRESS; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; THERAPY EFFECT; UPREGULATION; VASCULAR DISEASE; VASOCONSTRICTION; ANIMAL; AORTA; CYTOLOGY; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY;

MUS;

ANIMALS; ANTIGENS, CD95; AORTA; CELL-DERIVED MICROPARTICLES; CHEMOKINE CCL2; CYCLOOXYGENASE 2; FAS LIGAND PROTEIN; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; MALE; METABOLIC SYNDROME X; MICE; MIDDLE AGED; NADPH OXIDASE; NITRIC OXIDE; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION;

EID: 81055129769     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0027809     Document Type: Article

References (42)

1. Chew GT, Gan SK, Watts GF, (2006) Revisiting the metabolic syndrome. Med J Aust 185: 445-449.
2. Sesti G, (2006) Pathophysiology of insulin resistance. Best Pract Res Clin Endocrinol Metab 20: 665-679.
3. Fulop T, Tessier D, Carpentier A, (2006) The metabolic syndrome. Pathol Biol (Paris) 54: 375-386.
4. Magliano DJ, Shaw JE, Zimmet PZ, (2006) How to best define the metabolic syndrome. Ann Med 38: 34-41.
5. Wilson PW, D'Agostino RB, Parise H, Sullivan L, Meigs JB, (2005) Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation 112: 3066-3072.
6. Hugel B, Martinez MC, Kunzelmann C, Freyssinet JM, (2005) Membrane microparticles: two sides of the coin. Physiology (Bethesda) 20: 22-27.
7. Martinez MC, Tesse A, Zobairi F, Andriantsitohaina R, (2005) Shed membrane microparticles from circulating and vascular cells in regulating vascular function. Am J Physiol Heart Circ Physiol 288: H1004-1009.
8. Martinez MC, Andriantsitohaina R. Microparticles in angiogenesis: therapeutic potential. Circ Res 109: 110-119.
9. Martinez MC, Tual-Chalot S, Leonetti D, Andriantsitohaina R. Microparticles:targets and tools in cardiovascular disease. Trends Pharmacol Sci doi:101016/jtips.2011.06.005.
10. Tual-Chalot S, Leonetti D, Andriantsitohaina R, Martinez MC. Microvesicles: intercellular vectors of biological messages. Mol Interv 11: 88-94.
11. Freyssinet JM, (2003) Cellular microparticles: what are they bad or good for? J Thromb Haemost 1: 1655-1662.
12. Agouni A, Lagrue-Lak-Hal AH, Ducluzeau PH, Mostefai HA, Draunet-Busson C, et al. (2008) Endothelial dysfunction caused by circulating microparticles from patients with metabolic syndrome. Am J Pathol 173: 1210-1219.
13. Mostefai HA, Meziani F, Mastronardi ML, Agouni A, Heymes C, et al. (2008) Circulating microparticles from patients with septic shock exert protective role in vascular function. Am J Respir Crit Care Med 178: 1148-1155.
14. Gonzalez-Quintero VH, Smarkusky LP, Jimenez JJ, Mauro LM, Jy W, et al. (2004) Elevated plasma endothelial microparticles: preeclampsia versus gestational hypertension. Am J Obstet Gynecol 191: 1418-1424.
15. Priou P, Gagnadoux F, Tesse A, Mastronardi ML, Agouni A, et al. Endothelial dysfunction and circulating microparticles from patients with obstructive sleep apnea. Am J Pathol 177: 974-983.
16. Arteaga RB, Chirinos JA, Soriano AO, Jy W, Horstman L, et al. (2006) Endothelial microparticles and platelet and leukocyte activation in patients with the metabolic syndrome. Am J Cardiol 98: 70-74.
17. Chironi G, Simon A, Hugel B, Del Pino M, Gariepy J, et al. (2006) Circulating leukocyte-derived microparticles predict subclinical atherosclerosis burden in asymptomatic subjects. Arterioscler Thromb Vasc Biol 26: 2775-2780.
18. Nagata S, Golstein P, (1995) The Fas death factor. Science 267: 1449-1456.
19. Sata M, Suhara T, Walsh K, (2000) Vascular endothelial cells and smooth muscle cells differ in expression of Fas and Fas ligand and in sensitivity to Fas ligand-induced cell death: implications for vascular disease and therapy. Arterioscler Thromb Vasc Biol 20: 309-316.
20. Fukuo K, Hata S, Suhara T, Nakahashi T, Shinto Y, et al. (1996) Nitric oxide induces upregulation of Fas and apoptosis in vascular smooth muscle. Hypertension 27: 823-826.
21. Schaub FJ, Han DK, Liles WC, Adams LD, Coats SA, et al. (2000) Fas/FADD-mediated activation of a specific program of inflammatory gene expression in vascular smooth muscle cells. Nat Med 6: 790-796.
22. Schaub FJ, Liles WC, Ferri N, Sayson K, Seifert RA, et al. (2003) Fas and Fas-associated death domain protein regulate monocyte chemoattractant protein-1 expression by human smooth muscle cells through caspase- and calpain-dependent release of interleukin-1alpha. Circ Res 93: 515-522.
23. Tesse A, Martinez MC, Hugel B, Chalupsky K, Muller CD, et al. (2005) Upregulation of proinflammatory proteins through NF-kappaB pathway by shed membrane microparticles results in vascular hyporeactivity. Arterioscler Thromb Vasc Biol 25: 2522-2527.
24. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, et al. (2005) Diagnosis and management of the metabolic syndrome. An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Executive summary. Cardiol Rev 13: 322-327.
25. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, et al. (2005) Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 112: 2735-2752.
26. Martin S, Tesse A, Hugel B, Martinez MC, Morel O, et al. (2004) Shed membrane particles from T lymphocytes impair endothelial function and regulate endothelial protein expression. Circulation 109: 1653-1659.
27. Meziani F, Tesse A, David E, Martinez MC, Wangesteen R, et al. (2006) Shed membrane particles from preeclamptic women generate vascular wall inflammation and blunt vascular contractility. Am J Pathol 169: 1473-1483.
28. Agouni A, Mostefai HA, Porro C, Carusio N, Favre J, et al. (2007) Sonic hedgehog carried by microparticles corrects endothelial injury through nitric oxide release. Faseb J 21: 2735-2741.
29. Mostefai HA, Agouni A, Carusio N, Mastronardi ML, Heymes C, et al. (2008) Phosphatidylinositol 3-kinase and xanthine oxidase regulate nitric oxide and reactive oxygen species productions by apoptotic lymphocyte microparticles in endothelial cells. J Immunol 180: 5028-5035.
30. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, et al. (2002) Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 3: RESEARCH0034.
31. Charo IF, Taubman MB, (2004) Chemokines in the pathogenesis of vascular disease. Circ Res 95: 858-866.
32. Mostefai HA, Andriantsitohaina R, Martinez MC, (2008) Plasma membrane microparticles in angiogenesis: role in ischemic diseases and in cancer. Physiol Res 57: 311-320.
33. Tesse A, Meziani F, David E, Carusio N, Kremer H, et al. (2007) Microparticles from preeclamptic women induce vascular hyporeactivity in vessels from pregnant mice through an overproduction of NO. Am J Physiol Heart Circ Physiol 293: H520-525.
34. Tesse A, Al-Massarani G, Wangensteen R, Reitenbach S, Martinez MC, et al. (2008) Rosiglitazone, a peroxisome proliferator-activated receptor-gamma agonist, prevents microparticle-induced vascular hyporeactivity through the regulation of proinflammatory proteins. J Pharmacol Exp Ther 324: 539-547.
35. Hansson GK, Geng YJ, Holm J, Hardhammar P, Wennmalm A, et al. (1994) Arterial smooth muscle cells express nitric oxide synthase in response to endothelial injury. J Exp Med 180: 733-738.
36. Tesse A, Martinez MC, Meziani F, Hugel B, Panaro MA, et al. (2006) Origin and biological significance of shed-membrane microparticles. Endocr Metab Immune Disord Drug Targets 6: 287-294.
37. Pacher P, Beckman JS, Liaudet L, (2007) Nitric oxide and peroxynitrite in health and disease. Physiol Rev 87: 315-424.
38. Paravicini TM, Touyz RM, (2008) NADPH oxidases, reactive oxygen species, and hypertension: clinical implications and therapeutic possibilities. Diabetes Care 31 (Suppl 2): S170-180.
39. Seizer P, Gawaz M, May AE, (2008) Platelet-monocyte interactions-a dangerous liaison linking thrombosis, inflammation and atherosclerosis. Curr Med Chem 15: 1976-1980.
40. Ehrenschwender M, Wajant H, (2009) The role of FasL and Fas in health and disease. Adv Exp Med Biol 647: 64-93.
41. Geng YJ, Henderson LE, Levesque EB, Muszynski M, Libby P, (1997) Fas is expressed in human atherosclerotic intima and promotes apoptosis of cytokine-primed human vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 17: 2200-2208.
42. Aktan F, (2004) iNOS-mediated nitric oxide production and its regulation. Life Sci 75: 639-653.